Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study

ConclusionsThis post-marketing analysis indicates that switching to silodosin from tamsulosin or naftopidil significantly improved symptoms associated with BPH, and silodosin was well tolerated in Japanese patients.

http://link.springer.com/10.1007/s40268-018-0258-4

Source: Drugs in R&D - January 3, 2019 Category: Drugs & Pharmacology Source Type: research